Shuangying Liu

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 392 citations · Full text

Drug Target, Anaplastic Lymphoma Kinase, Tumor Biology +18

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 357 citations · Full text

Drug Target, Immunology, Molecular Biology +25

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 321 citations · Full text

Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors

Anna Kohlmann, Stephan G. Zech, Feng Li et al. · Journal of Medicinal Chemistry · 2013 · 83 citations · Full text

LARS2 Regulates Apoptosis via ROS‐Mediated Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Ovarian Granulosa Cells

Shujun Feng, Shan Wan, Shuangying Liu et al. · Oxidative Medicine and Cellular Longevity · 2022 · 62 citations · Full text